KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Cash from Investing Activities (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed Cash from Investing Activities for 11 consecutive years, with $142000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Cash from Investing Activities rose 107.16% to $142000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $14.8 million, a 52.87% increase, with the full-year FY2023 number at $12.0 million, up 156.52% from a year prior.
  • Cash from Investing Activities was $142000.0 for Q3 2024 at Palvella Therapeutics, down from $2.2 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $18.4 million in Q3 2020 to a low of -$16.9 million in Q1 2022.
  • A 5-year average of $2.1 million and a median of $414000.0 in 2020 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 1662.86% in 2022; the steepest drop was 60428.57% in 2022.
  • Palvella Therapeutics' Cash from Investing Activities stood at $14.9 million in 2020, then tumbled by 102.3% to -$342000.0 in 2021, then soared by 423.68% to $1.1 million in 2022, then skyrocketed by 211.56% to $3.4 million in 2023, then crashed by 95.88% to $142000.0 in 2024.
  • Per Business Quant, the three most recent readings for PVLA's Cash from Investing Activities are $142000.0 (Q3 2024), $2.2 million (Q2 2024), and $9.0 million (Q1 2024).